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Background: Streptococcus suis is divided into 29 serotypes based on a serological reaction against the capsular
polysaccharide (CPS). Multiplex PCR tests targeting the cps locus are also used to determine S. suis serotypes, but
they cannot differentiate between serotypes 1 and 14, and between serotypes 2 and 1/2. Here, we developed a
pipeline permitting in silico serotype determination from whole-genome sequencing (WGS) short-read data that can
readily identify all 29 S. suis serotypes.
Results: We sequenced the genomes of 121 strains representing all 29 known S. suis serotypes. We next combined
available software into an automated pipeline permitting in silico serotyping of strains by differential alignment of
short-read sequencing data to a custom S. suis cps loci database. Strains of serotype pairs 1 and 14, and 2 and 1/2
could be differentiated by a missense mutation in the cpsK gene. We report a 99 % match between coagglutination-
and pipeline-determined serotypes for strains in our collection. We used 375 additional S. suis genomes downloaded
from the NCBI’s Sequence Read Archive (SRA) to validate the pipeline. Validation with SRA WGS data resulted in a 92 %
match. Included pipeline subroutines permitted us to assess strain virulence marker content and obtain multilocus
sequence typing directly from WGS data.
Conclusions: Our pipeline permits rapid and accurate determination of S. suis serotype, and other lineage
information, directly from WGS data. By discriminating between serotypes 1 and 14, and between serotypes 2
and 1/2, our approach solves a three-decade longstanding S. suis typing issue.
Keywords: Streptococcus suis, Serotyping, Whole-genome sequencing, Short-readsBackground
Streptococcus suis is a major swine pathogen responsible
for severe economic losses to the porcine industry, and
an emerging zoonotic agent of disease [1, 2]. S. suis
strains are typed based on a serological reaction against
the capsular polysaccharide (CPS), whose biosynthesis
machinery is encoded by genes located in the cps locus
[3, 4]. Thirty-five different S. suis serotypes were originally
described (serotypes 1–34 and serotype 1/2) [5]. However,
serotypes 20, 22, 26, 33, 32 and 34 have recently been* Correspondence: nahuel.fittipaldi@oahpp.ca
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[6, 7]. Therefore, the S. suis species currently comprises a
total of 29 serotypes. Accurate S. suis serotype identifica-
tion is of significant epidemiological importance for the
control of swine infections, since different serotypes are
prevalent in different parts of the world [8]. Although it is
widely considered the gold standard for typing, serology is
expensive and time-consuming, and can only be per-
formed at select reference laboratories. In addition, ser-
ology cannot readily discriminate between serotypes 2 and
1/2, or between serotypes 1 and 14, which cross-react on
the coagglutination test [9]. Recently, elaborated PCR
schemes targeting the cps locus permitting rapid “serotyp-
ing” of S. suis strains were described [10, 11]. However,
due to the similar gene content of their respective cps loci,le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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2 and 1/2, and between serotypes 1 and 14 [10, 11]. Accur-
ately distinguishing between serotypes 2 and 1/2, as well
as between 1 and 14, is important since, based on current
data, serotypes 2 and 14 are heavily associated with zoo-
notic disease [12].
Recent advances in whole-genome sequencing (WGS)
technologies now permit the sequencing of hundreds of
bacterial genomes rapidly and relatively inexpensively.
WGS approaches are revolutionizing microbial typing in
both the human and veterinary fields, and enhancing
public health objectives such as disease surveillance,
epidemic investigation and infection control [13–15].
In addition to typing, WGS data analysis permits rapid
identification of known and putative virulence factors
present in the genomes of the strains of interest [16, 17].
Here we report the development of a user-friendly bio-
informatics pipeline running on the Linux operating sys-
tem that combines available free software, and which can
be used for rapid determination of S. suis serotype directly
from the short-read WGS data. The pipeline correctly dis-
criminates between all 29 S. suis serotypes, and permits to
differentiate between serotypes 1 and 14, and between se-
rotypes 2 and 1/2. The pipeline also uses the short-read
WGS data to determine strain multilocus sequence typing
(MLST) sequence type (ST) and virulence factor content.
Methods
Whole-genome sequencing
We sequenced the genomes of 121 S. suis strains belong-
ing to 29 different serotypes (Additional file 1: Table S1).
The strains used in this study have not been collected
specifically for this study. They were part of the author’s
extensive collection of clinical isolates. Serotyping was
performed using the coagglutination test as previously
described [9]. Strains were grown overnight in Todd-
Hewitt broth (BD Bioscience, San Jose, CA) supplemented
with 0.2 % yeast extract at 37 °C with 5 % CO2. DNA was
prepared using the QIAamp DNA minikit (Qiagen, To-
ronto, Canada) following the manufacturer’s protocol for
Gram-positive organisms. Genomic libraries were prepared
using Nextera XT kits (Illumina, San Diego, CA) and
sequenced as paired-ends using either a HiSeq 2500
(125 bp + 125 bp) or a MiSeq (150 bp + 150 bp) instru-
ments (Illumina). Generated data was deposited in the
Sequence Read Archive (SRA) under the Accession
Numbers provided in Additional file 1: Table S1.
Capsular typing pipeline
Our pipeline automates the execution of software that
aligns WGS short-reads to custom or available S. suis
sequence databases and permits subsequent sequence
comparisons. Briefly, the nucleotide sequence of gene
recN, which is unique to the S. suis species [18], wasretrieved from the genome of S. suis serotype 2 strain
NSUI002 (GenBank Accession Number CP011419), and
included as S. suis species control. Short-read WGS data
were then aligned to the recN sequence using the program
SRST2, a software originally conceived as a means to de-
rive MLST information from bacterial short-read WGS
data [19]. However, SRST2 can be used to derive any typ-
ing information of interest if an appropriate sequence
database is provided, as exemplified by reported pipelines
permitting emm typing of Group A Streptococcus from
short-read WGS data [13]. We next created a S. suis cps
database by first downloading from GenBank sequences
corresponding to each of the 27 S. suis cps loci differenti-
able by a multiplex PCR (Additional file 1: Table S2). Sero-
type specific cps loci regions were defined using in silico
PCR and the primer sequences described in a multiplex
PCR assay designed to differentiate S. suis serotypes [20].
Specific sequences for serotype defining amplicons were
extracted using custom scripts. After species confirmation,
our pipeline uses SRST2 to align short-read WGS data to
the abovementioned cps database and makes an initial
serotype assignment. Serotype pairs 1 and 14, and 2 and
1/2 cannot be identified directly using SRST2 (a limitation
of the multiplex PCR assay, and thus of our custom cps
amplicon database). Therefore, to resolve these ambiguous
results, our pipeline next uses custom scripts that identify
single-nucleotide polymorphisms in the cps2K gene of
every strain identified as a putative serotype 1 or 14, or as
putative serotype 2 or 1/2, followed by translation of the
amino acid sequences for each strain. Based on the amino
acid present at position 161 of the predicted translated se-
quence of the cpsK gene, the pipeline assigns the final
serotype for the strain.
Sanger sequencing of the cpsK locus
In order to confirm findings for the differences in the
cpsK gene, we amplified a fragment of interest from
DNA of 13 additional serotype 1/2 strains using primers
cpsK-F (5’-GTTGCTGGTTATGATAGGGTAG-3’) and
cpsK-R (5’-AACTCATAGAGCAAGCGATAAG-3’), followed
by Sanger sequencing of the generated amplicon using
the same primers.
MLST, virulence marker gene content, and validation of
the pipeline
The S. suis MLST database was downloaded from the S.
suis MLST website available at ssuis.mlst.net. Sequence
types (STs) were determined directly from the short-read
WGS data using SRST2 [19]. The sequences of virulence
marker genes epf, sly, and mrp were compared between
multiple strains, and conserved subsequences were ex-
tracted. The presence or absence of these virulence fac-
tors was determined based on short-read alignment to
these conserved sequences using SRST2. Pipeline partial
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content) were then combined in a final output file. To
validate our pipeline, previously generated WGS short-
read data for 367 S. suis strains were downloaded from
the SRA (Additional file 1: Table S3).
Results and Discussion
Species confirmation
We sequenced the genomes of 121 S. suis strains repre-
senting 29 different serotypes. The coverage across the
genome was on average 56X, considering an average S.
suis genome size of 2.2 Mbp (Additional file 1: Table
S1). An overview of our pipeline is presented in Fig. 1.
Essentially, the pipeline uses SRST2 [19] to align the
short-read WGS data to various databases that are modifi-
able. In a first iteration, short-reads are aligned against the
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Fig. 1 Schematic of the S. suis serotyping pipeline. The pipeline takes in S. su
to the species S. suis by aligning reads to the gene recN using SRST2 software.
instances to identify serotype, MLST information, and virulence gene content u
between serotype 1 and serotype 14, or between serotype 2 and serotype 1/2
results). Final serotype determination results are then combined with MLST anfor this gene. Although the specificity of this gene for the
S. suis species has been verified extensively [18], here we
assessed recN specificity using short-read WGS generated
in our laboratories for 1,040 strains of Streptococcus aga-
lactiae, Streptococcus pyogenes, Streptococcus pneumoniae,
Streptococcus pluranimalium, Streptococcus porcinus,
Actinobacillus pleuropneumoniae and Listeria monocy-
togenes. None of the genomes of the strains of these
species were recN positive (data not shown).
Capsular typing from short-read WGS
Next, our pipeline aligns short-read WGS data to a cus-
tom cps database. The cps database is constructed based
on expected amplicons defined by Kerdsin et al. [20].
Since this database cannot differentiate between serotypes
1 and 14 or between serotypes 2 and 1/2, it represents 27
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e gene sequence
is WGS reads in fastq format and first confirms that the isolate belongs
Once species has been confirmed, SRST2 is invoked in three parallel
sing provided databases. The serotyping component cannot differentiate
without additional comparison of the sequences of the cps2K gene (see
d virulence results to provide the user a single output file
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two serotype pairs. A total of 120 strains were assigned a
serotype, or putative serotype in the case of the above-
mentioned serotype pairs by short-read alignment to the
custom cps database (Additional file 1: Table 1). One
strain, typed by coagglutination as serotype 8, was not
assigned a serotype by our pipeline, i.e., it was designated
as “non-typable”. To investigate this unexpected result, we
manually inspected the BAM file containing the alignment
of the reads of this strain to the cps8 locus. Manual inspec-
tion revealed several areas of very low short-read coverage.
Alignment of reads of this strain to de novo genome as-
semblies for other serotype 8 strains generated using the
A5 pipeline [21] revealed that coverage across the genomeTable 1 Serotype determination using the S. suis serotyping pipelin
Serotype Number of strains with this serotype
on the coagglutination test
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bAll six serotype 8 strains were assigned to serotype 8 by our pipeline after reseque
been sequenced at low read coverage due to technical issues during genomic libraof this non-typable strain was uneven (biased, likely the
result of suboptimal tagmentation during library prepara-
tions), and some areas of the cps8 locus had a coverage
depth of 1X (data not shown). The program SRST2 re-
quires, by default, a read coverage of at least 3X in order
to identify an allele [19]. Thus, this result exemplifies one
limitation of our pipeline, which is that adequate and even
short-read coverage is necessary to confidently identify se-
rotypes. Resequencing of the genome of this isolate per-
mitted us to reach a coverage of 331 X. With these novel
data, the pipeline correctly assigned the isolate to serotype
8. As a general rule, we recommend that users of our pipe-
line generate WGS data with an across-genome read
coverage of at least 30X, which is in accordance with thee
ified in Number of strains identified in
pipeline second pass






























o serotype 2 and serotype 14 strains are presumptively assigned to serotype 1
ncing of the genome of one serotype isolate whose genome had originally
ries preparation
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ommendations for the use of next-generation sequencing
in clinical laboratories [22]. Alternatively, in cases where a
serotype is not assigned, expert users that have low cover-
age samples for which a positive recN result is obtained
could manually inspect the BAM files reporting alignment
to each type-specific cps sequence before concluding the
strain is non-typable.
Differentiating between serotypes 1 and 14 and between
serotypes 2 and 1/2
Genetic studies have shown that the cps loci of S. suis
serotypes 1 and 14 have exact gene content [23]. Simi-
larly, the cps loci of serotypes 2 and 1/2 strains have the
same gene content [23]. We hypothesized that differ-
ences exist at the single-nucleotide level in the cps loci
of those pairs of serotypes, and that those differences
permit to resolve each serotype pair into individual types.
To test the initial hypothesis, we de novo assembled the
short-reads of all 7 isolates of each of these serotypes in-
cluded in our collection using the A5 pipeline [21]. The de
novo assemblies were screened to identify each cps loci,
which were then aligned using ClustalW [24] and interro-
gated for polymorphisms unique to each serotype. The
analysis revealed that all serotype 2 and all serotype 14Fig. 2 Schematics of cps loci and identification of a single-nucleotide polym
and 2 and 1/2. The cps loci of serotypes 1 and 14 are identical in gene con
analysis of all available serotype 1, 14, 2 and 1/2 strains in our collection re
strains, and that serotype 2 strains consistently differed from serotype 1/2 s
which is predicted to result in an amino acid change from tryptophan to c
between those otherwise unresolvable serotype pairs and assign the seroty
the first step of the pipeline to differentiate serotypes 1 and 14 as well as sstrains had a G nucleotide at position 483 of the cpsK
gene, while all serotype 1 and all serotype 1/2 strains con-
tained either a C or T at that nucleotide position. Thus,
the predicted sequence of the CpsK protein in serotypes 2
and 14 possess amino acid tryptophan at position 161,
while the predicted sequence of the CpsK protein in sero-
types 1/2 and 1 has amino acid cysteine at this position
(Fig. 2). The genome sequence of a serotype 1/2 strain
from China has been published [25]. When we examined
the reported sequence of the cpsK gene of this Chinese
strain (GenBank Accession Number NC_017619), we did
not find the abovementioned polymorphism, i.e., the cpsK
gene of the Chinese strain has a G nucleotide at position
483 resulting in a TGG codon. Since this reported cpsK
sequence raises concerns about the universality of the
polymorphism permitting differentiation of serotypes 2
and 1/2 identified in this study, and in order to study
the issue in more detail, we performed Sanger sequencing
of the cpsK gene of 13 additional serotype 1/2 strains recov-
ered in Canada. In agreement with our genomic findings,
Sanger sequencing identified that the cpsK gene of these
additional serotype 1/2 strains contained a T nucleotide at
position 483. Moreover, when we used external WGS
data to validate our pipeline (see below), none of the 10
genomes of serotype 1/2 strains reported in a previousorphism permitting differentiation of the S. suis serotypes 1 and 14,
tent (top), as are the cps loci of serotypes 2 and 1/2 (bottom). However,
vealed that serotype 14 strains consistently differed from serotype 1
trains by a single-nucleotide change (G to T or C) in the cpsK gene,
ysteine. Our pipeline uses this amino acid change to differentiate
pe to the strain under investigation. Red bars indicate regions used in
erotypes 2 and 1/2 from other serotypes
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the serotype 1/2 Chinese strain, but, instead, they had
one of the polymorphisms described here. CpsK is a glyco-
syltransferase predicted to add galactose (in serotypes 2
and 14) or N-acetylgalactosamine (in serotypes 1 and 1/2)
to the polysaccharide chain [27–29]. We speculate that
the polymorphism at amino acid position 161 of CpsK is
critical in defining the sugar that this enzyme recognizes.
Using targeted mutagenesis (replacement of CpsK amino
acid residue at position 161 from W to C), we have very
recently been able to switch the capsular polysaccharide
from 2 to 1/2 in a serotype 2 strain. Conversely, after
inverting the substitution, i.e. C to W substitution, we
transformed a serotype 1/2 strain into a serotype 2 strain
(Roy et al., manuscript in preparation). We thus believe
that either the reported genome sequence of the Chinese
serotype 1/2 strain contains an error in the cpsK gene se-
quence or that the strain was misidentified as serotype 1/2
when it is, in fact, serotype 2. Unfortunately, short-reads
for the Chinese strain are not available to confirm this
speculation.
Our pipeline takes advantage of the abovementioned
polymorphisms in cpsK to discriminate between these
otherwise unresolvable pairs of serotypes. Briefly, after
alignment to the custom cps database, the pipeline as-
signs a presumptive label of “serotype 1” to the potential
pair 1–14 and a presumptive label of “serotype 2” to the
potential pair 2-1/2. Next, it invokes a second mapping
step, which by aligning short-reads of the strain under
investigation to cps2K sequences, identifies SNPs and
outputs the predicted amino acid sequence of CpsK.
This amino acid sequence is then scanned for the pres-
ence of a tryptophan or a cysteine amino acid residue at
position 161. A final serotype assignment (1 or 14, or 2
or 1/2) is then made based on the predicted translated
codon. Using this second step, our pipeline matched
coagglutination results in 120 cases (all strains, with
the exception of the abovementioned serotype 8 strain;
Table 1).
Validation of the pipeline with external datasets
Next, we sought to validate our pipeline using available
WGS datasets generated by others [26]. To this end, we
downloaded from the SRA WGS short-read data for
375 S. suis strains. Of them, 329 represented 13 sero-
types (Additional file 1: Table S3), whereas 46 strains
had been described as non-typable by serology [26].
Based on the presence of serotype specific sequences, we
were able to assign a serotype to 38 of the 46 non-typable
strains using our pipeline. It must be noted, however, that
serotype assignment by our pipeline cannot predict
whether a strain actually expresses capsular material. As
reported previously [30], mutations in cps loci genes,
which occur frequently and which our pipeline is notdesigned to detect, as well as insertion of mobile genetic
elements in the cps locus of any given S. suis strain, may
lead to the absence of capsule expression. However, sero-
type determination of unencapsulated strains is useful to
understand a variety of strain traits, including their origin
and evolutionary path. The remaining eight strains present
in the external collection that were reported as non-
typable [26] did not match any of the sequences in our
cps database, and thus were also identified as non-typable
by our pipeline. The genomes of these eight strains were
de novo assembled and BLASTN comparisons against the
reference sequences of all 29 cps loci were carried out. We
were unable to identify homology to any of the 29 cps loci.
Thus, we conclude that these eight strains may represent
novel S. suis serotypes.
Our pipeline and previously reported serotyping re-
sults [26] agreed in 303 of the 329 strains in the external
collection (92 %). We examined the 26 mismatched
isolates by manual inspection of BAM files containing
the short-read data alignments to each of the specific
cps regions defining serotypes in our database. The
analysis revealed very poor short-read alignment to se-
quences for the loci encoding the previously reported
serologically-determined serotypes [26]. On the other
hand, in 22 out of these 26 cases, BAM inspection re-
vealed very good coverage relative to the serotype-specific
sequences corresponding to the serotype identified by our
pipeline. However, in 4 cases, BAM file examination did
not show good alignments to any of the sequences in the
database. To unambiguously determine the quality of our
pipeline results, WGS short-read data for these 26 strains
were de novo assembled and local BLASTN comparisons
were performed to identify the cps loci of the strains. In 22
cases, the strains had the cps loci expected for the serotype
identified by our pipeline (Additional file 1: Figures S1 to
S22), and not the one expected based on the reported
serological results [26]. The remaining four strains
were identified as non-typable by our pipeline. We
were unable to assign any of these four strains to any
known S. suis serotype based on BLASTN comparisons
to known cps loci of the de novo assemblies (Additional
file 1: Figures S23 to S26). Therefore, we conclude that
these 4 strains are bona fide nontypable S. suis strains,
while the 26 other strains had been mistyped by the
serological method(s) used to ascertain their serotype
[26].
MLST determination and virulence factor content
Using the MLST database for S. suis, our pipeline next
invokes SRST2 to determine the MLST STs of each
strain (Additional file 1: Table S1). The vast majority of the
strains were assigned to known STs already described in
the S. suis MLST database, but we also identified 41 novel
STs. Our pipeline was also used to determine presence or
Athey et al. BMC Microbiology  (2016) 16:162 Page 7 of 8absence of virulence factors (Additional file 1: Table S1).
The virulence factor database provided with our pipeline
was designed as a proof of principle, and only screens for
conserved regions of mrp, epf and sly genes, encoding a
muramidase-released protein, an extracellular protein
factor, and a hemolysin known as suilysin, respectively
[31–34]. Users may add any virulence gene of interest
to the pipeline virulence database. Results are presented in
Additional file 1: Table S1. Our virulence results for mrp,
epf and sly matched those described in previous studies in
serotypes 1, 1/2, 2, 3, 7, and 9 [35, 36], which so far have
been studied in a more consistent fashion than other S.
suis serotypes.
Conclusions
Serotyping of S. suis strains is crucial to infection control
efforts and to reduce the possibility of zoonotic disease
outbreaks [1, 2]. The need to accurately differentiate be-
tween serotypes 1 and 14, and between serotypes 2 and
1/2 is emphasized by the zoonotic potential of serotypes
2 and 14 [37]. Here, we show that WGS short-read data,
which now can be generated rapidly and relatively inex-
pensively for large numbers of strains, can be used to
precisely identify the serotype of S. suis strains, as well
as to obtain other relevant strain information in an auto-
mated fashion. One limitation of our pipeline, which is
common to previously reported multiplex PCR tests tar-
geting the cps locus [10, 11], is that we only analyzed
one or a few representative strains of rare serotypes such
as 6, 11, 15, 21, 25. Analysis of a more important number
of strains of these rare serotypes, when they become avail-
able, should increase the confidence in a pipeline positive
result for these serotypes. Importantly, our pipeline can
differentiate with high accuracy between serotypes 1 and
14, as well as between serotypes 2 and 1/2, which cannot
be resolved by available multiplex PCR assays, or which
require multiple serological reactions using specific anti-
sera available only at a few selected reference laboratories
worldwide. Compared to serology, one limitation of our
WGS approach is that it does not identify whether a strain
actually expresses a capsule. However, insights gained by
determining the cps locus type of serologically non-
typable strains are important for phylogenetic and evolu-
tion purposes. As demonstrated here when validating our
pipeline with external data, it is not uncommon that S.
suis isolates are mistyped using serological assays. Thus,
using our pipeline reduces the variability introduced by
different personnel performing such serological tests. If
strains must be confirmed by using serological means, our
pipeline can pinpoint the specific serotype that needs to
be tested, thus saving time and money by eliminating the
need for multiple serological reactions. The pipeline is
open source and available for download from https://
github.com/streplab/SsuisSerotyping_pipeline.Additional file
Additional file 1: S. suis strains used in this study; serotypes and
accession numbers for reference capsule type sequences used in this
study; information and pipeline results of S. suis strains downloaded from
the Sequence Read Archive and comparison of cps loci of selected S. suis
strains This supplementary file contains: 1) three supplementary Tables, 2)
26 supplementary Figures. (PDF 7086 kb)
Abbreviations
CPS, capsular polysaccharide; MLST, multi-locus sequence type; PCR, polymerase
chain reaction; SNP, single nucleotide polymorphism; SRA, sequence read
archive; SRST2, short read sequencing typing version 2; ST, sequence type;
WGS, whole genome sequencing
Acknowledgements
We thank Aimin Li (Genome Core facility, Public Health Ontario Laboratory)
and Dax Torti (Donelly Center, University of Toronto) for Illumina sequencing
of our strains. We are grateful to Lucy Weinert and Dan Tucker (University of
Cambridge) for critical reading of an early version of this manuscript.
Funding
Funding was provided by Public Health Ontario PIF 2014–005.
Authors’ contributions
TBTA, MG and NF designed research. TBTA coded the pipeline scripts. TBTA,
ST and SL performed research. DT and MG contributed materials. TBTA, ST,
SL, DT, MG and NF analyzed data. TBTA and NF wrote the first draft of the
manuscript. All authors have read and approved the final version of this
manuscript.
Availability of supporting data
Whole genome sequencing short-read data are available from the Short Read
Archive under the accession number SRP067927. The pipeline is available for
download from github https://github.com/streplab/SsuisSerotyping_pipeline.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Ethics Review Board of Public Health
Ontario.
Author details
1Public Health Ontario Toronto Laboratory, 661 University Avenue, Toronto,
ON, M5G 1M1 Canada. 2Groupe de Recherche sur les Maladies Infectieuses
du Porc, Faculty of Veterinary Medicine, University of Montreal, St-Hyacinthe,
QC, Canada. 3Bacterial and Parasitic Diseases Research Division, National
Institute of Animal Health, National Agriculture and Food Research
Organization, Tsukuba, Japan. 4The United Graduate School of Veterinary
Sciences, Gifu University, Gifu, Japan. 5Department of Laboratory Medicine
and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON,
Canada.
Received: 24 February 2016 Accepted: 15 July 2016
References
1. Gottschalk M. Streptococcosis. In: Zimmerman JJKL, Ramirez A, Schwartz JK,
Stevenson G, editors. Diseases of swine. Ames: Wiley Publishers; 2011. p. 841–55.
2. Gottschalk M, Xu J, Calzas C, Segura M. Streptococcus suis: a new emerging
or an old neglected zoonotic pathogen? Fut Microbiol. 2010;5(3):371–91.
3. Smith HE, Damman M, van der Velde J, Wagenaar F, Wisselink HJ,
Stockhofe-Zurwieden N, Smits MA. Identification and characterization of
the cps locus of Streptococcus suis serotype 2: the capsule protects
against phagocytosis and is an important virulence factor. Infec Immun.
1999;67(4):1750–6.
Athey et al. BMC Microbiology  (2016) 16:162 Page 8 of 84. Smith HE, de Vries R, van't Slot R, Smits MA. The cps locus of Streptococcus
suis serotype 2: genetic determinant for the synthesis of sialic acid. Microb
Pathog. 2000;29(2):127–34.
5. Gottschalk M, Higgins R, Jacques M, Mittal KR, Henrichsen J. Description of 14
new capsular types of Streptococcus suis. J Clin Microbiol. 1989;27(12):2633–6.
6. Hill JE, Gottschalk M, Brousseau R, Harel J, Hemmingsen SM, Goh SH.
Biochemical analysis, cpn60 and 16S rDNA sequence data indicate that
Streptococcus suis serotypes 32 and 34, isolated from pigs, are Streptococcus
orisratti. Vet Microbiol. 2005;107(1–2):63–9.
7. le Tien HT, Nishibori T, Nishitani Y, Nomoto R, Osawa R. Reappraisal of the
taxonomy of Streptococcus suis serotypes 20, 22, 26, and 33 based on
DNA-DNA homology and sodA and recN phylogenies. Vet Microbiol.
2013;162(2–4):842–9.
8. Goyette-Desjardins G, Auger J-P, Xu J, Segura M, Gottschalk M. Streptococcus
suis, an important pig pathogen and emerging zoonotic agent: an update
on the worldwide distribution based on serotyping and sequence typing.
Emerg Microbes Infect. 2014;3, e45.
9. Gottschalk M, Higgins R, Boudreau M. Use of polyvalent coagglutination
reagents for serotyping of Streptococcus suis. J Clin Microbiol.
1993;31(8):2192–4.
10. Liu Z, Zheng H, Gottschalk M, Bai X, Lan R, Ji S, Liu H, Xu J. Development of
multiplex PCR assays for the identification of the 33 serotypes of Streptococcus
suis. PloS One. 2013;8(8), e72070.
11. Okura M, Lachance C, Osaki M, Sekizaki T, Maruyama F, Nozawa T, Nakagawa I,
Hamada S, Rossignol C, Gottschalk M, et al. Development of a two-step
multiplex PCR assay for typing of capsular polysaccharide synthesis gene
clusters of Streptococcus suis. J Clin Microbiol. 2014;52(5):1714–9.
12. Gottschalk M, Segura M, Xu J. Streptococcus suis infections in humans: the
Chinese experience and the situation in North America. Anim Health Res
Rev. 2007;8(1):29–45.
13. Athey TB, Teatero S, Li A, Marchand-Austin A, Beall BW, Fittipaldi N. Deriving
group A Streptococcus typing information from short-read whole-genome
sequencing data. J Clin Microbiol. 2014;52(6):1871–6.
14. Holmes EC, Ghedin E, Miller N, Taylor J, Bao Y, St George K, Grenfell BT,
Salzberg SL, Fraser CM, Lipman DJ, et al. Whole-genome analysis of human
influenza A virus reveals multiple persistent lineages and reassortment
among recent H3N2 viruses. PLoS Biol. 2005;3(9), e300.
15. Koser CU, Ellington MJ, Cartwright EJ, Gillespie SH, Brown NM, Farrington M,
Holden MT, Dougan G, Bentley SD, Parkhill J, et al. Routine use of microbial
whole genome sequencing in diagnostic and public health microbiology.
PLoS Pathog. 2012;8(8), e1002824.
16. Bertelli C, Greub G. Rapid bacterial genome sequencing: methods and
applications in clinical microbiology. Clin Microbiol Infec. 2013;19(9):803–13.
17. Gilchrist CA, Turner SD, Riley MF, Petri Jr WA, Hewlett EL. Whole-genome
sequencing in outbreak analysis. Clin Microbiol Rev. 2015;28(3):541–63.
18. Ishida S, le HT T, Osawa R, Tohya M, Nomoto R, Kawamura Y, Takahashi T,
Kikuchi N, Kikuchi K, Sekizaki T. Development of an appropriate PCR system
for the reclassification of Streptococcus suis. J Microbiol Met. 2014;107:66–70.
19. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, Zobel J,
Holt KE. SRST2: Rapid genomic surveillance for public health and hospital
microbiology labs. Genome Med. 2014;6(11):90.
20. Kerdsin A, Akeda Y, Hatrongjit R, Detchawna U, Sekizaki T, Hamada S,
Gottschalk M, Oishi K. Streptococcus suis serotyping by a new multiplex PCR.
J Med Microbiol. 2014;63(Pt 6):824–30.
21. Tritt A, Eisen JA, Facciotti MT, Darling AE. An integrated pipeline for de
novo assembly of microbial genomes. PLoS One. 2012;7(9), e42304.
22. Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, Friez
MJ, Funke BH, Hegde MR, Lyon E, et al. ACMG clinical laboratory standards
for next-generation sequencing. Genet Med. 2013;15(9):733–47.
23. Okura M, Takamatsu D, Maruyama F, Nozawa T, Nakagawa I, Osaki M,
Sekizaki T, Gottschalk M, Kumagai Y, Hamada S. Genetic analysis of capsular
polysaccharide synthesis gene clusters from all serotypes of Streptococcus
suis: potential mechanisms for generation of capsular variation. Appl
Environ Microbiol. 2013;79(8):2796–806.
24. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity
of progressive multiple sequence alignment through sequence weighting,
position-specific gap penalties and weight matrix choice. Nucleic Acids Res.
1994;22(22):4673–80.
25. Zhang A, Yang M, Hu P, Wu J, Chen B, Hua Y, Yu J, Chen H, Xiao J, Jin M.
Comparative genomic analysis of Streptococcus suis reveals significant
genomic diversity among different serotypes. BMC Genomics. 2011;12:523.26. Weinert LA, Chaudhuri RR, Wang J, Peters SE, Corander J, Jombart T, Baig A,
Howell KJ, Vehkala M, Valimaki N, et al. Genomic signatures of human and
animal disease in the zoonotic pathogen Streptococcus suis. Nat Commun.
2015;6:6740.
27. Van Calsteren MR, Gagnon F, Calzas C, Goyette-Desjardins G, Okura M,
Takamatsu D, Gottschalk M, Segura M. Structure determination of
Streptococcus suis serotype 14 capsular polysaccharide. Biochem Cell Biol.
2013;91(2):49–58.
28. Van Calsteren MR, Gagnon F, Lacouture S, Fittipaldi N, Gottschalk M.
Structure determination of Streptococcus suis serotype 2 capsular
polysaccharide. Biochem Cell Biol. 2010;88(3):513–25.
29. Van Calsteren MR, Goyette-Desjardins G, Gagnon F, Okura M, Takamatsu D,
Roy R, Gottschalk M, Segura M. Explaining the serological characteristics of
Streptococcus suis serotypes 1 and 1/2 from their capsular polysaccharide
structure and biosynthesis. J Biol Chem. 2016.
30. Lakkitjaroen N, Takamatsu D, Okura M, Sato M, Osaki M, Sekizaki T. Loss of
capsule among Streptococcus suis isolates from porcine endocarditis and its
biological significance. J Med Microbiol. 2011;60(Pt 11):1669–76.
31. Gottschalk MG, Lacouture S, Dubreuil JD. Characterization of Streptococcus
suis capsular type 2 haemolysin. Microbiology. 1995;141(Pt 1):189–95.
32. Jacobs AA, Loeffen PL, van den Berg AJ, Storm PK. Identification,
purification, and characterization of a thiol-activated hemolysin (suilysin) of
Streptococcus suis. Infec Immun. 1994;62(5):1742–8.
33. Smith HE, Reek FH, Vecht U, Gielkens AL, Smits MA. Repeats in an
extracellular protein of weakly pathogenic strains of Streptococcus suis type
2 are absent in pathogenic strains. Infec Immun. 1993;61(8):3318–26.
34. Smith HE, Vecht U, Gielkens AL, Smits MA. Cloning and nucleotide
sequence of the gene encoding the 136-kilodalton surface protein
(muramidase-released protein) of Streptococcus suis type 2. Infec Immun.
1992;60(6):2361–7.
35. Berthelot-Herault F, Morvan H, Keribin AM, Gottschalk M, Kobisch M.
Production of muraminidase-released protein (MRP), extracellular factor (EF)
and suilysin by field isolates of Streptococcus suis capsular types 2, 1/2, 9, 7
and 3 isolated from swine in France. Vet Res. 2000;31(5):473–9.
36. Silva LM, Baums CG, Rehm T, Wisselink HJ, Goethe R, Valentin-Weigand P.
Virulence-associated gene profiling of Streptococcus suis isolates by PCR. Vet
Microbiol. 2006;115(1–3):117–27.
37. Smith HE, Veenbergen V, van der Velde J, Damman M, Wisselink HJ, Smits
MA. The cps genes of Streptococcus suis serotypes 1, 2, and 9: development
of rapid serotype-specific PCR assays. J Clin Microbiol. 1999;37(10):3146–52.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
